Bedrijfsoverzicht
AN2 Therapeutics, Inc. is a biopharmaceutical enterprise dedicated to the discovery and development of novel small molecule therapeutics designed to address specific medical conditions. The company operates within the healthcare sector, specifically functioning in the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at creating new treatments. As of the latest data, the firm holds a market capitalization of $106.77 million, employs a workforce of 21 individuals, and reports no available revenue figures for the trailing twelve months. These valuation metrics indicate that the company maintains a relatively small market presence typical of early-stage or growth-oriented biotechnology firms that prioritize clinical progress over immediate revenue generation. The absence of reported revenue combined with a market cap under $110 million suggests the business is currently in a phase where capital allocation is directed almost exclusively toward advancing its clinical pipeline, such as the phase 3 trial for epetraborole, rather than scaling commercial operations.
Financiële gezondheid
The financial statements for AN2 Therapeutics, Inc. show a Net Income (TTM) of $-35,174,000, while Revenue (TTM) and EBITDA are listed as N/A, highlighting a cost structure where expenses significantly exceed any current income generation. This substantial gap between the lack of revenue and the negative net income reveals that the company's operations are heavily reliant on cash burn to fund research and development efforts rather than profit margins from sales. The company reports Free Cash Flow of $-18,382,124, which indicates a continuous outflow of cash that requires ongoing financing to maintain operations and sustain its financial flexibility over the long term. Regarding profitability metrics, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, indicating that the company has not yet achieved commercial profitability or that revenue is insufficient to cover the direct costs of production and general operations. On the liability side, the company holds $58.00 million in cash and zero in debt, creating a balance sheet that is highly conservative and free from leverage obligations. This liquidity position is further supported by a Current Ratio of 6.87, which signifies a robust ability to meet short-term obligations with current assets, providing a substantial buffer against immediate financial pressures. Return on Equity stands at -52.1% and Return on Assets is -30.9%, metrics that reveal management is currently utilizing shareholder capital and assets to fund expansion rather than generating returns, a common characteristic of pre-revenue biotechnology companies.
Waarderingsbeoordeling
Valuation multiples for AN2 Therapeutics, Inc. present a mixed picture typical of development-stage biotech firms, with a P/E Ratio (TTM) listed as N/A due to the absence of earnings and a Forward P/E of -3.71 reflecting negative earnings projections in the near term. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a significant turnaround or successful clinical outcome before the company can generate positive earnings per share. The Price to Book ratio is 1.53, suggesting that the market values the company at a 53% premium over its net book value, likely driven by the potential value of its intellectual property and pipeline assets rather than tangible assets alone. Alternative valuation metrics such as Price to Sales and EV/EBITDA are both N/A, which indicates that traditional sales-based or earnings-based valuation methods are not applicable at this stage of the company's lifecycle. The stock's price action over the past year ranges between a 52-Week High of $6.91 and a 52-Week Low of $1.00, with the current market price trading at a specific point within this volatile range. A Beta of -1.32 is recorded for the stock, a unique and statistically rare metric that suggests the share price moves inversely to the broader market or exhibits extreme volatility not directly correlated with standard market indices.
Growth & Income
Growth metrics for AN2 Therapeutics, Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) both as N/A, as the company has not yet established a consistent revenue stream to calculate year-over-year growth rates. The absence of historical revenue data means that traditional comparisons of earnings growing faster or slower than revenue are not currently possible, leaving the growth profile entirely dependent on future clinical trial successes and regulatory approvals. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that all available cash flow is reinvested into research, development, and operational expansion rather than being distributed to shareholders. This reinvestment strategy is standard for biotechnology firms that must preserve capital to fund expensive clinical trials and manufacturing processes to bring new drugs to market. The overall growth and income profile is currently defined by high volatility and zero income generation, with the company's value contingent on the successful advancement of its pipeline candidates like epetraborole through phase 3 trials and subsequent commercialization.